GRDN - Guardian Pharmacy S... Stock Analysis | Stock Taper
Logo
Guardian Pharmacy Services, Inc.

GRDN

Guardian Pharmacy Services, Inc. NYSE
$33.51 1.33% (+0.44)

Market Cap $2.12 B
52w High $37.43
52w Low $17.78
P/E 49.28
Volume 164.92K
Outstanding Shares 63.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $377.43M $58.37M $9.82M 2.6% $0.16 $23.61M
Q2-2025 $344.33M $55.57M $9.03M 2.62% $0.15 $18.25M
Q1-2025 $329.31M $51.34M $9.45M 2.87% $0.15 $18.54M
Q4-2024 $338.57M $50.35M $11.94M 3.53% $0.2 $21.8M
Q3-2024 $314.39M $165.49M $-112.64M -35.83% $-2 $-99.62M

What's going well?

Revenue and profits are both rising at a healthy pace. The company is controlling costs well, leading to better operating margins. There are no one-time charges, so results reflect the true business performance.

What's concerning?

Profit margins are still low, and a high tax rate is limiting how much of the revenue turns into profit. Lack of detail on R&D and marketing spending makes it hard to judge long-term growth investments.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $36.49M $390.04M $194.54M $183.76M
Q2-2025 $18.82M $356.33M $176.66M $169.56M
Q1-2025 $14M $334M $170.78M $156.09M
Q4-2024 $4.66M $320.81M $170.83M $142.67M
Q3-2024 $37.22M $348.03M $214.13M $127.57M

What's financially strong about this company?

GRDN has nearly doubled its cash this quarter, paid down debt, and grown equity. The company is mostly funded by shareholders, not lenders, and has plenty of liquid assets to cover its bills.

What are the financial risks or weaknesses?

Payables and receivables are both rising, which could signal slower collections or delayed payments to suppliers. Goodwill and intangibles are a quarter of assets, so there's some risk if acquisitions don't perform.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $9.59M $28.17M $-8.97M $-1.53M $17.67M $22.96M
Q2-2025 $8.83M $19.94M $-13M $-2.11M $4.82M $15.63M
Q1-2025 $9.27M $17.55M $-5.54M $-2.67M $9.34M $11.74M
Q4-2024 $11.94M $22.34M $-6.62M $-48.27M $-32.56M $17.84M
Q3-2024 $-105.82M $-2.16M $-7.08M $44.93M $35.68M $-7.29M

What's strong about this company's cash flow?

Cash from operations and free cash flow both jumped this quarter. The company is self-funding, paying down debt, and building a healthy cash cushion.

What are the cash flow concerns?

A big part of this quarter’s cash boost came from delaying payments to suppliers, which may not be sustainable. Receivables and inventory are also rising, which could hurt future cash flow if not managed.

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Corporate Segment
Corporate Segment
$330.00M $340.00M $380.00M

Q3 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

GRDN combines strong revenue growth with a clearer, healthier balance sheet than in prior years, underpinned by consistent positive operating and free cash flow. Its niche focus on long‑term care, assisted living, and behavioral health, delivered through a hybrid local‑national model, creates close customer relationships and a service proposition that is harder to commoditize. A growing suite of technology tools further embeds the company in client workflows, enhancing retention and supporting its acquisition‑driven expansion strategy.

! Risks

The most pressing concern is the dramatic deterioration in profitability, driven by a surge in operating expenses that turned a growing business into a loss‑making one. If elevated overhead levels persist, they could structurally compress returns, especially in a reimbursement‑constrained healthcare environment. Rising goodwill and intangible assets reflect acquisition risk and potential future impairments. The company also faces regulatory uncertainty, intense competition from larger and smaller rivals, and the challenge of aligning its innovation and growth ambitions with disciplined cost control and capital allocation.

Outlook

The forward picture hinges on execution. If management can bring operating costs back in line with revenue and extract the expected benefits from its acquisitions and technology investments, the combination of strong top‑line growth, improved leverage, and solid cash generation could support a healthier long‑term financial profile. If, however, the recent cost structure proves sticky or competitive and regulatory pressures intensify, margins may remain under pressure despite rising sales and a stronger balance sheet. Monitoring the trajectory of operating expenses, margin recovery, and sustained free cash flow over the next few years will be key to understanding how GRDN’s story evolves.